Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Incidence and severity of SARS-CoV-2 infections in liver and kidney transplant recipients in the post-vaccination era: Real-life data from Denmark

Sebastian Rask Hamm | Omid Rezahosseini | Dina Leth Møller | Josefine Amalie Loft | Johan Runge Poulsen | Jenny Dahl Knudsen | Martin Schou Pedersen | Kristian Schønning | Zitta Barrella Harboe | Allan Rasmussen | Søren Schwartz Sørensen | Susanne Dam Nielsen

1Viro-immunology Research Unit, Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
2Department of Clinical Microbiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
3Department of Pulmonary and Infectious Diseases, Hospital of North Zealand, Copenhagen University Hospital, Hillerød, Denmark
4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
5Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
6Department of Nephrology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Correspondence
Susanne Dam Nielsen, Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, København, Denmark.
Email: susanne.dam.poulsen@regionh.dk

Funding information
Det Frie Forskningsråd; Læge Sophus Carl Emil Friis og hustru Olga Doris Friis’ Legat; Novo Nordisk Fonden; Rigshospitalet

Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; DDV, Danish Vaccination Register; ICU, intensive care unit; IQR, interquartile range; MiBa, Danish Microbiology Database; mRNA, messenger RNA; mTOR, mammalian target of rapamycin; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; SOT, solid organ transplant.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.
1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), was associated with substantial morbidity and mortality in solid organ transplant (SOT) recipients in the pre-vaccination era with reports on hospitalization rates ranging from 31 to 89%,\textsuperscript{1–5} intensive care unit (ICU) admission ranging from 11% to 33%,\textsuperscript{1–4,6} and mortality ranging from 5% to 27%.\textsuperscript{1–4,6–8}

Development and administration of vaccines is the mainstay of preventive efforts to curb the COVID-19 pandemic, and at-risk individuals have been prioritized for early vaccination with messenger RNA (mRNA) vaccines.\textsuperscript{9} In a phase III trial, the BNT162b2 mRNA vaccine demonstrated excellent efficacy in protection from symptomatic COVID-19 within the first 2 months following vaccination with a declining efficacy from 2 to 6 months after vaccination.\textsuperscript{10} However, SOT recipients were excluded from the phase III trials,\textsuperscript{11} and data on real-life vaccine effectiveness in SOT recipients are lacking. Reports suggest that in the first months after vaccination, SARS-CoV-2 vaccines effectively protect SOT recipients against infections.\textsuperscript{12–14} However, humoral immunity wanes over time in both immunocompetent individuals\textsuperscript{15,16} and SOT recipients,\textsuperscript{17,18} and a higher proportion of SOT recipients reach low concentrations of antibodies and neutralizing capacity of antibodies 6 months after vaccination than immunocompetent individuals.\textsuperscript{18} Furthermore, reports showing that protection against infection wanes over time in immunocompetent individuals\textsuperscript{19–21} have led to administration of a third and, subsequently, a fourth vaccine dose to SOT recipients in many countries.\textsuperscript{9}

After vaccination, SOT recipients remain at higher risk of SARS-CoV-2 infections than immunocompetent individuals.\textsuperscript{22} A Spanish study found lower mortality in vaccinated SOT recipients than in unvaccinated SOT recipients after mRNA vaccination,\textsuperscript{14} and an English study reported that vaccination with BNT162b2 did not reduce risk of death after SARS-CoV-2 infection in SOT recipients. However, to date, no large study has investigated SARS-CoV-2-related morbidity and mortality in a homogenously vaccinated cohort of SOT recipients in the post-vaccination era. Furthermore, no large study including mild and asymptomatic infections has investigated morbidity and mortality in SOT recipients after SARS-CoV-2 infection in the post-vaccination era.

We aimed to determine the incidence of first-positive SARS-CoV-2 polymerase chain reaction (PCR) test in SOT recipients in the first year after vaccination was initiated in Denmark. Furthermore, we aimed to investigate treatments, hospitalizations and ICU admissions 30 days after first-positive SARS-CoV-2 PCR test, and 30-day mortality in SOT recipients with first-positive SARS-CoV-2 PCR test who were vaccinated or unvaccinated at the time of infection.

2 | METHODS

2.1 | Study design

In this retrospective cohort study, we included kidney and liver transplant recipients transplanted at Copenhagen University Hospital, Rigshospitalet, Denmark between January 1, 1990 and December 1, 2021, who were ≥18 years old, living in Denmark, alive on December 27, 2020, received either BNT162b2 vaccination or no vaccination and had no history of positive SARS-CoV-2 PCR test prior to inclusion. We excluded SOT recipients who had positive SARS-CoV-2 PCR prior to the inclusion date or received vaccines other than BNT162b2 (Figure 1). Rigshospitalet is a large tertiary hospital with a knowledge center and highly specialized functions in the field of solid organ transplantation, and it is the only liver transplant center in Denmark. In Denmark, vaccination against SARS-CoV-2 was initiated on December 27, 2020. SOT recipients were prioritized for early vaccination, and the vast majority of SOT recipients received BNT162b2 if vaccinated (>99%).

Data on clinical information, including demographics, comorbidities, transplant type, date of death, and use of immunosuppressive medication were collected from medical records. In patients with a positive SARS-CoV-2 PCR test, data on hospitalizations, COVID-19-related treatments, and admissions to intensive care units (ICU) were collected from medical records. Data on admissions to all healthcare facilities in Denmark were accessible and were used in the study. Data on vaccination status were collected from the Danish Vaccination Register (DDV). Since 2015 it has been mandatory to register all vaccines administered to Danish patients in DDV.\textsuperscript{23} Data on SARS-CoV-2 PCR tests were collected from the Danish Microbiology Database (MiBa),\textsuperscript{24} which contains complete data on all microbiological samples in Denmark including samples from both general practices, test centers, and hospitals. Other than SARS-CoV-2 PCR, rapid antigen test has been widely available and free of charge in Denmark. In case of a positive rapid antigen test, patients were recommended to have a PCR test. Furthermore, close contacts and symptomatic patients were recommended to have PCR rather than rapid antigen tests. The complete national coverage of MiBa and DDV\textsuperscript{23} combined with extensive and easily accessible free of charge PCR testing in Denmark during the study period allowed us to report all vaccinations and positive SARS-CoV-2 PCR tests from all sectors of the universal Danish healthcare system. In Denmark, extensive whole-genome sequencing of positive SARS-CoV-2 PCR tests was performed throughout 2021, with approximately 80% of positive PCR samples being successfully sequenced until the beginning of December 2021, when positive cases increased outnumbering the sequencing capacity after the introduction of the omicron variant.\textsuperscript{25}

The study was conducted following the declaration of Helsinki, and according to Danish legislation, the retrieval of data without collection of informed consent was approved by the institutional review board at the Center for Regional Development (R-20051155).

2.2 | Definitions

A participant was defined as vaccinated 14 days after receiving the second dose of BNT162b2 vaccine. A participant was defined as having received a third dose 14 days after receiving the third dose of BNT162b2 vaccine. None of the participants received a fourth dose
during the study period. An unvaccinated participant was defined as having received zero doses, having received one dose or being within the first 14 days after the second dose.

The duration of follow-up was defined as the number of days from "December 27, 2020" to "the time of the first-positive SARS-CoV-2 PCR test," "the time of death," or "December 27, 2021," whichever came first. Therefore, the duration of follow-up was shorter than 1 year for some patients.

COVID-19-related hospitalizations were defined as a hospital admission lasting more than 24 h within 30 days of a positive SARS-CoV-2 PCR test, where the patient presented at least one COVID-19-related symptom (cough, fever, myalgia, headache, dyspnea, sore throat, diarrhea, nausea/vomiting, loss of smell and taste, abdominal pain or rhinorrhea). In addition, if the patient was already hospitalized at the date of first-positive SARS-CoV-2 PCR test, the admission was defined as a COVID-19-related admission if the patient presented COVID-19-related symptoms as described above or was treated for COVID-19.

Admission to ICU was defined as an admission to ICU during a COVID-19-related hospitalization.

Participants who were transplanted after December 27, 2020 were defined as having delayed entry to the study.

2.3 | Study period

We started follow-up on December 27, 2020, when the first patient in Denmark was vaccinated, and ended the follow-up on December 27, 2021. For participants with delayed entry, the start of follow-up was the day of transplantation. In total, 107 participants had delayed entry. To assess incidence rates and cumulative incidences of first-positive SARS-CoV-2 PCR test, we censored the follow-up time on December 27, 2021, at the time of the first-positive SARS-CoV-2 PCR test, or at the time of death, whichever came first. To assess cumulative incidence of hospitalizations, admission to ICU, and mortality after the first-positive SARS-CoV-2 PCR test, all participants with a positive SARS-CoV-2 PCR test were followed for at least 30 days after the date of the first-positive test or to the time of death, whichever came first.

2.4 | Statistics

Normality was assessed by QQ-plots/normal probability plots. Continuous data were reported with medians and interquartile range (IQR). Categorical data were reported as frequency counts and percentages, and independency was tested by chi-square test or Fisher's test, as appropriate. Differences in continuous data were tested using the Mann–Whitney U test.

Incidence rates of first-positive SARS-CoV-2 PCR test in SOT recipients were calculated as the number of first-positive SARS-CoV-2 PCR tests per 1000 person-years at risk. Byar's approximation to the Poisson distribution was used to calculate 95% confidence intervals (CI). The cumulative incidence of first-positive SARS-CoV-2 PCR test in the follow-up period was calculated using
the Aalen–Johansen estimator with death as a competing risk. Gray’s test was used to test for the difference in cumulative incidence of first-positive SARS-CoV-2 PCR test in liver and kidney transplant recipients.

In a sensitivity analysis, we excluded transplant recipients transplanted after “December 27, 2020” to see if exclusions of participants with delayed entry affected the results.

Descriptive statistics were used to describe the characteristics of vaccinated and unvaccinated SOT participants with a positive SARS-CoV-2 PCR test.

Cumulative incidence of hospital admissions or admissions to ICU 30 days after first-positive SARS-CoV-2 PCR test was calculated using the Aalen–Johansen estimator with death as a competing risk. To test for differences in 30-day cumulative incidence of hospitalizations and admissions to ICU in vaccinated and unvaccinated SOT recipients after first-positive SARS-CoV-2 PCR test Gray’s test was used. Mortality 30 days after first-positive SARS-CoV-2 PCR test was calculated using the Kaplan–Meier estimator. The log-rank test was used to test for difference in 30-day mortality after first-positive SARS-CoV-2 PCR test in vaccinated and unvaccinated SOT recipients. To test for difference in 30-day cumulative incidence of hospitalizations in liver and kidney transplant recipients after first-positive SARS-CoV-2 PCR test Gray’s test was used.

A Cox regression model with monoclonal antibodies as time-updated variable was used to determine the risk factors of hospital admission due to COVID-19 in the first 30 days after the first-positive PCR test. Age, gender, type of transplanted organ, number of vaccine doses, treatment with outpatient monoclonal antibodies comorbidities, time from transplantation to infection, and immunosuppressive maintenance therapy were considered possible risk factors. In a multivariable analysis, we included age, transplanted organ, number of vaccine doses before infection, and outpatient monoclonal antibody treatment. The proportional hazard assumptions were tested using score residuals and found to be valid.

Analyses were performed using R version 4.0.3 (R Core Team, 2020, Vienna, Austria) and the packages epiR,27 survival, prodlim,28 fmsb, timereg, and cmprsk.29

3 | RESULTS

3.1 | Baseline clinical characteristics of SOT recipients

We included 1428 SOT recipients without a previous positive SARS-CoV-2 PCR test (Figure 1), of those 905 were kidney and 523 were liver transplant recipients. The median age at the start of follow-up (December 27, 2020) was 54 years (IQR 45–63), and 851 (59.6%) SOT recipients were male. The median time from transplantation to the start of follow-up was 6.1 years (range 0.0–30.0), with a minor difference between liver and kidney transplant recipients (Table 1). Furthermore, the distribution of comorbidities and use of immunosuppressive maintenance treatment differed between liver and kidney transplant recipients (Table 1).

3.2 | Follow-up

The study comprised of 1316 person-years of follow-up with a median follow-up of 365 days (IQR 365–365). Reasons for follow-up of <365 days were death in 42 SOT recipients (2.9%), SARS-CoV-2 infection during the study period in 143 SOT recipients (10%), and delayed entry in 107 SOT recipients transplanted after December 27, 2020 (7.5%). Seventy-eight of the 107 SOT recipients transplanted after December 27, 2020 were vaccinated before transplantation. Although, only four of those were infected during follow-up. For vaccinated SOT recipients, the median time from the start of follow-up to the time that the SOT recipient was considered vaccinated (i.e., >14 days after the second dose) was 76 days (IQR 46–94, Figure S1). The median (IQR) time from vaccination to a positive PCR was 247 (191–272) days and ranged from 14 to 317 days.

3.3 | Incidence rate and cumulative incidence of first-positive SARS-CoV-2 PCR test

During follow-up, 143 SOT recipients had at least one positive SARS-CoV-2 PCR test. The incidence rate of first-positive SARS-CoV-2 PCR test was 109 per 1000 person-years (95% CI: 92–128), and the median time from the start of follow-up to first-positive SARS-CoV-2 PCR test was 314 days (IQR 179–346). In kidney transplant recipients the incidence rate was 127 per 1000 person-years (95% CI: 105–153), while it was 77 per 1000 person-years (95% CI: 56–105) in liver transplant recipients. The incidence rate ratio was 1.64 (1.13–2.38, p = .008). The cumulative incidence of first-positive SARS-CoV-2 PCR test on December 27, 2021, was 10.4% (95% CI: 8.8–12.0). The cumulative incidence of first-positive SARS-CoV-2 PCR test was higher in the kidney transplant recipients compared to the liver transplant recipients (11.6% [95% CI: 9.4–13.8] vs. 7.4% [95% CI: 5.1–9.8], p = .009, Figure 2). In a sensitivity analysis excluding participants with delayed entry, we found that all estimates and p-values remain robust (Table S1).

3.4 | Clinical characteristics of SOT recipients at the time of the first-positive SARS-CoV-2 PCR test

Of the 143 SOT recipients with a positive SARS-CoV-2 PCR test, 33 were unvaccinated at the time of infection, and 110 were
vaccinated (Table 2). There were no significant differences in clinical characteristics between vaccinated and unvaccinated SOT recipients with positive SARS-CoV-2 PCR test, nor was there a difference in the type of transplanted organ (Table 2). However, the median date of first-positive SARS-CoV-2 PCR test was February 1, 2021, in unvaccinated and November 24, 2021, in vaccinated SOT recipients. Consequently, SARS-CoV-2 variant differed between vaccinated and unvaccinated positive SARS-CoV-2 PCR tests, wild-type being most frequent among those who were unvaccinated at time of infection and delta being most frequent among those who were vaccinated at the time of infection ($p < .001$, Table 2). Furthermore, in Denmark, preventive use of monoclonal antibodies after SARS-CoV-2 infection in high-risk groups became available in December 2021. Until then, the use of mAbs after SARS-CoV-2 infection was not universal. Therefore, more SOT recipients who were vaccinated at the time of first-positive SARS-CoV-2 PCR test received monoclonal antibody treatment than those who were unvaccinated at the time of first-positive SARS-CoV-2 PCR test (34.5% vs. 6.1%, $p = .001$, Table 2).

3.5 Outcomes after first-positive SARS-CoV-2 PCR test in SOT recipients

Forty-five SOT recipients were hospitalized due to COVID-19 within 30 days of their first-positive SARS-CoV-2 PCR test. The 30-day cumulative incidence of hospitalizations after first-positive SARS-CoV-2 PCR test was 31.5% (95% CI: 23.9–39.1), and this was lower in vaccinated than unvaccinated SOT recipients (26.4% [95% CI: 18.1–34.6] vs. 48.5% [95% CI: 31.4–65.5], $p = .011$, Figure 3). Eleven SOT recipients were admitted to ICU during hospitalization due to COVID-19. The 30-day cumulative incidence of ICU admissions was 7.7% (95% CI: 3.3–12.1), and this was lower in vaccinated than unvaccinated SOT recipients (4.5% [95% CI: 0.7–8.4] vs. 18% [95% CI: 5.0–31.3], $p = .011$, Figure 3). The 30-day all-cause mortality after

### Table 1 Baseline characteristics of all liver and kidney transplant recipients

|                       | All SOT recipients, n = 1428 | Liver transplant recipients, n = 523 (36.6%) | Kidney transplant recipients, n = 905 (63.4%) |
|------------------------|------------------------------|---------------------------------------------|---------------------------------------------|
| Age, median (IQR)      | 54 (45–63)                   | 55 (46–63)                                  | 53 (44–63)                                  |
| Sex (male), n (%)      | 851 (59.6%)                  | 294 (56.2%)                                 | 557 (61.5%)                                 |
| Time since transplantation at end of follow-up in years, median (IQR) | 6.1 (2.6–10.4)               | 5.1 (1.8–9.7)                               | 6.6 (3.0–10.7)                               |
| Comorbidities, n (%)   |                              |                                             |                                             |
| Cardiovascular disease  | 717 (68.5%)                  | 145 (36.2%)                                 | 572 (88.5%)                                 |
| Chronic pulmonary disease | 115 (11.0%)                 | 42 (10.5%)                                  | 73 (11.3%)                                  |
| Diabetes mellitus      | 253 (24.2%)                  | 89 (22.2%)                                  | 164 (25.4%)                                 |
| Immunosuppressive treatment, n (%) |                       |                                             |                                             |
| No antimetabolites     | 206 (14.4%)                  | 121 (23.1%)                                 | 85 (9.4%)                                   |
| Azathioprine           | 127 (8.9%)                   | 36 (6.9%)                                   | 91 (10.1%)                                  |
| Calcineurin inhibitor (Ciclosporin, Tacrolimus) | 1277 (89.4%)               | 475 (90.8%)                                 | 802 (88.6%)                                 |
| mTOR inhibitor (Sirolimus, Everolimus) | 86 (6.0%)                  | 32 (6.1%)                                   | 54 (6.0%)                                   |
| Corticosteroids        | 1082 (75.8%)                 | 256 (48.9%)                                 | 826 (91.3%)                                 |
| Number of vaccine doses at time of death or December 27, 2021 |                       |                                             |                                             |
| 0                      | 74 (5.2%)                    | 21 (4.0%)                                   | 53 (5.9%)                                   |
| 1                      | 5 (0.4%)                     | 3 (0.6%)                                    | 2 (0.2%)                                    |
| 2                      | 127 (8.9%)                   | 45 (8.6%)                                   | 82 (9.1%)                                   |
| 3                      | 1222 (85.6%)                 | 454 (86.8%)                                 | 768 (84.9%)                                 |

Abbreviations: IQR, interquartile range; mTOR, mammalian target of rapamycin.

*Missing data from 381 participants (122 liver transplant recipients and 259 kidney transplant recipients).*
first-positive SARS-CoV-2 PCR test was 3.5% (95% CI: 0.5–6.5) and there was a lower 30-day all-cause mortality in the vaccinated than in unvaccinated SOT recipients (1.8% [95% CI: 0.0–4.3] vs. 9.1% [95% CI: 0.0–18.9], \( p = .047 \), Figure 3).

There was no significant difference in 30-day cumulative incidence of hospitalizations after first-positive SARS-CoV-2 PCR test between kidney and liver transplant recipients (35.2% [95% CI: 26.1–44.4] vs. 21.1% [95% CI: 8.1–34.0], \( p = .101 \), Figure 4). None of the liver transplant recipients were admitted to ICU or died within 30 days of the first-positive SARS-CoV-2 PCR test. In kidney transplant recipients the 30-day cumulative incidence of ICU admissions after first-positive SARS-CoV-2 PCR test was 10.5% (95% CI: 4.6–16.3, Figure 4), and the 30-day all-cause mortality was 4.8% (95% CI: 0.7–8.2, Figure 4). Furthermore, 30-day cumulative incidence of hospitalizations was lower among participants receiving outpatient mAb treatment than those who did not after first-positive SARS-CoV-2 PCR test (41.7% [95% CI: 32.2–51.3], \( p < .001 \), Figure S2).

### 3.6 Treatment of SOT recipients hospitalized due to COVID-19

The median duration of hospital stay due to COVID-19 was 6 days (IQR 4–12). Among the 45 SOT recipients who were hospitalized, there was a tendency toward a shorter stay at hospital in those who were vaccinated at the time of infection compared to those who were unvaccinated (median 4 days vs 12 days, \( p = .058 \)). Among the hospitalized SOT recipients, 42% received oxygen therapy, 42% received Remdesivir treatment, 64.4% received dexamethasone treatment, 4.4% received convalescent plasma, and 51% received monoclonal antibody treatment (Table 3). In-hospital treatments did not differ between those who were vaccinated and unvaccinated at the time of infection except for monoclonal antibody treatment, which was more frequent in the vaccinated SOT recipients than the unvaccinated (62.5% vs. 18.8%, \( p = .004 \), Table 3).
## 3.7 Risk factors for hospital admission after infection

In the univariable Cox proportional hazards model, participants who received three doses of vaccine or patients who received outpatient monoclonal antibodies had an HR of 0.11 ([95% CI, 0.01–0.76], \( p < .026 \)) and 0.31 ([95% CI, 0.15–0.67], \( p < .003 \)) for hospital admission, respectively. In the multivariable model, containing age, type of transplanted organ, number of vaccine doses, and outpatient monoclonal antibodies, patients who had three doses of vaccine had an HR of 0.42 ([95% CI, 0.19–0.89], \( p < .025 \)). Moreover, treatment with outpatient monoclonal antibodies had an HR of 0.15 ([95% CI, 0.02–1.05], \( p = .057 \)) for the hospital admission (Table 4).

## 4 DISCUSSION

In this large retrospective cohort study with real-life data from liver and kidney transplant recipients in Denmark, the cumulative incidence of first-time positive SARS-CoV-2 PCR test was 10% in the

| TABLE 2 Clinical characteristics of SOT recipients at the time of first-positive SARS-CoV-2 PCR test according to vaccination status at time of infection |
|-----------------------------------------------|
| All SOT recipients, \( n = 143 \) | Unvaccinated, \( n = 33 \) (23.1%) | Vaccinated, \( n = 110 \) (76.9%) | \( p \)-value |
| Age at time of first-positive SARS-CoV-2 PCR test, median (IQR) | 49 (40–59) | 46 (31–60) | 50 (42–58) | 0.369 |
| Sex (male), n (%) | 91 (63.6%) | 17 (51.5%) | 74 (67.3%) | 0.149 |
| Time from transplantation to first-positive SARS-CoV-2 PCR test in years, median (IQR) | 6.0 (2.5–10.0) | 5.0 (2.0–10.0) | 6.0 (3.0–9.8) | 0.751 |
| Transplant type, n (%) | | | | |
| Kidney | 105 (73.4%) | 26 (78.8%) | 79 (71.8%) | 0.569 |
| Liver | 38 (26.6%) | 7 (21.2%) | 31 (28.2%) | |
| Comorbidities, n (%) | | | | |
| Cardiovascular disease | 95 (66.4%) | 23 (69.7%) | 72 (65.5%) | 0.808 |
| Chronic pulmonary disease | 17 (11.9%) | 5 (15.2%) | 12 (10.9%) | 0.543 |
| Diabetes mellitus | 32 (22.4%) | 6 (18.2%) | 26 (23.6%) | 0.674 |
| Immunosuppressive treatment at time of first-positive SARS-CoV-2 PCR test, n (%) | | | | |
| No antimetabolites | 13 (9.1%) | 2 (6.1%) | 11 (10.0%) | 0.593 |
| Mycophenolate | 121 (84.6%) | 28 (84.8%) | 93 (84.5%) | |
| Azathioprine | 9 (6.3%) | 3 (9.1%) | 6 (5.5%) | |
| Calcineurin inhibitor (Ciclosporin, Tacrolimus) | 135 (94.4%) | 31 (93.9%) | 104 (94.5%) | 1.00 |
| mTOR inhibitor (Sirolimus, Everolimus) | 4 (2.8%) | 2 (6.1%) | 2 (1.8%) | 0.228 |
| Corticosteroids | 122 (85.3%) | 29 (87.9%) | 93 (84.5%) | 0.783 |
| Number of vaccine doses at time of first-positive SARS-CoV-2 PCR test, n (%) | | | | |
| 0 | 29 (20.3%) | 29 (87.9%) | 0 (0%) | <0.001 |
| 1 | 4 (2.8%) | 4 (12.1%) | 0 (0%) | |
| 2 | 46 (32.2%) | 0 (0%) | 46 (41.8%) | |
| 3 | 64 (44.8%) | 0 (0%) | 64 (58.2%) | |
| SARS-CoV-2 variant\( ^a \), n (%) | | | | |
| Wild-type | 8 (11.3%) | 8 (61.5%) | 0 (0.0%) | <0.001 |
| Alpha | 7 (9.9%) | 2 (15.4%) | 5 (8.6%) | |
| Delta | 51 (71.8%) | 3 (23.1%) | 48 (82.8%) | |
| Omicron | 5 (7.0%) | 0 (0.0%) | 5 (8.6%) | |
| Outpatient monoclonal antibody treatment with Sotrovimab | 37 (28.0%) | 2 (6.1%) | 35 (31.8%) | 0.003 |
| Outpatient monoclonal antibody treatment with Regn-Cov2 | 3 (2.7%) | 0 (0%) | 3 (2.7%) | 1.00 |

Abbreviations: IQR, interquartile range; mTOR, mammalian target of rapamycin; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory coronavirus 2.

\( ^a \)Missing data from 72 infections (20 unvaccinated and 52 vaccinated).
FIGURE 3 Cumulative incidence of hospitalizations, ICU admissions, and mortality 30 days after first-positive SARS-CoV-2 PCR test in vaccinated and unvaccinated SOT recipients. (A) Cumulative incidence of hospitalizations in vaccinated and unvaccinated SOT recipients due to COVID-19 in the first 30 days after positive SARS-CoV-2 PCR test with day of first-positive SARS-CoV-2 PCR test as day 0. (B) Cumulative incidence of ICU admissions in vaccinated and unvaccinated SOT recipients due to COVID-19 in the first 30 days after first-positive SARS-CoV-2 PCR test with day of first-positive SARS-CoV-2 PCR test as day 0. (C) All-cause mortality in vaccinated and unvaccinated SOT recipients in the first 30 days after first-positive SARS-CoV-2 PCR test with day of first-positive SARS-CoV-2 PCR test as day 0. The yellow line represents SOT recipients who were vaccinated at time of infection, while black line represents SOT recipients who were unvaccinated at time of infection. [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 4  Cumulative incidence of hospitalizations, ICU admissions, and mortality 30 days after first-positive SARS-CoV-2 PCR test in kidney and liver transplant recipients. (A) Cumulative incidence of hospitalizations in SOT recipients due to COVID-19 in the first 30 days after first-positive SARS-CoV-2 PCR test with the day of first-positive SARS-CoV-2 PCR test as day 0. (B) Cumulative incidence of ICU admissions in liver and kidney transplant recipients in the first 30 days after first-positive SARS-CoV-2 PCR test with the day of first-positive SARS-CoV-2 PCR test as day 0. (C) All-cause mortality in liver and kidney transplant recipients in the first 30 days after first-positive SARS-CoV-2 PCR test with day of first-positive SARS-CoV-2 PCR test as day 0. The red line represents liver transplant recipients and the grey line represents kidney transplant recipients. [Color figure can be viewed at wileyonlinelibrary.com]
first year after BNT162b2 vaccination was initiated. Thirty days after first-positive SARS-CoV-2 PCR test, the cumulative incidence of hospitalizations was 31.5%. Vaccinated transplant recipients had a lower incidence of hospitalization, ICU admission, and a lower 30-day mortality, and there was a tendency toward shorter hospital stay in vaccinated than in unvaccinated SOT recipients. Risk of hospital admission was 58% lower in participants who received three vaccine doses. Moreover, there was a tendency toward lower risk of

| TABLE 3 Clinical characteristics, treatment, and outcomes in SOT recipients hospitalized due to COVID-19 |
|---------------------------------------------------------------|--------------|-------------|----------------|-------------|
| All SOT recipients, n = 45                                   | Unvaccinated, n = 16 (35.6%) | Vaccinated, n = 29 (64.4%) | p-value      |
| Age at time of first-positive SARS-CoV-2 PCR test, median (IQR) | 55 (45–66) | 47 (33–66) | 56 (47–61) | 0.331 |
| Sex (male), n (%)                                             | 32 (71.1%) | 7 (43.8%)  | 25 (86.2%) | 0.005 |
| Time from transplantation to first-positive SARS-CoV-2 PCR test in years, median (IQR) | 5.0 (2.0–8.0) | 4.5 (2.0–10.2) | 5.0 (3.0–8.0) | 0.962 |
| Transplant type, n (%)                                        |              |              |              |       |
| Kidney                                                         | 37 (82.2%)  | 14 (87.5%)  | 23 (79.3%) | 0.692 |
| Liver                                                          | 8 (17.8%)   | 2 (12.5%)   | 6 (20.7%)  |       |
| Comorbidities, n (%)                                           |              |              |              |       |
| Cardiovascular disease                                        | 33 (73.3%)  | 11 (68.8%)  | 22 (75.9%) | 0.728 |
| Chronic pulmonary disease                                      | 6 (13.3%)   | 4 (25.0%)   | 2 (6.9%)   | 0.166 |
| Diabetes mellitus                                              | 13 (28.9%)  | 4 (25.0%)   | 9 (31.0%)  | 0.743 |
| Immunosuppressive treatment at time of first-positive SARS-CoV-2 PCR test, n (%) |              |              |              |       |
| No antimetabolites                                             |              |              |              |       |
| Azathioprine                                                   | 2 (4.4%)    | 1 (6.2%)    | 1 (3.4%)   |        |
| Calcineurin inhibitor (Ciclosporin, Tacrolimus)                | 41 (91.1%)  | 15 (93.8%)  | 26 (89.7%) | 1.00  |
| mTOR inhibitor (Sirolimus, Everolimus)                        | 3 (6.7%)    | 1 (6.2%)    | 2 (6.9%)   | 1.00  |
| Corticosteroids                                                | 40 (88.9%)  | 15 (93.8%)  | 25 (86.2%) | 0.641 |
| Number of vaccine doses at time of first-positive SARS-CoV-2 PCR test, n (%) |              |              |              |       |
| 0                                                              |              |              |              | <0.001 |
| 1                                                              |              |              |              | <0.001 |
| 2                                                              |              |              |              |       |
| 3                                                              |              |              |              |       |
| SARS-CoV-2 variant a, n (%)                                    |              |              |              |       |
| Wild-type                                                      | 6 (26.1%)   | 6 (75.0%)   | 0 (0.0%)   | <0.001 |
| Alpha                                                          | 2 (8.7%)    | 1 (12.5%)   | 1 (6.7%)   |       |
| Delta                                                          | 15 (65.2%)  | 1 (12.5%)   | 14 (93.3%) |       |
| Omicron                                                        | 0 (0.0%)    | 0 (0.0%)    | 0 (0.0%)   |       |
| In-hospital treatment, n (%)                                   |              |              |              |       |
| Oxygen therapy                                                 | 19 (42.2%)  | 8 (50.0%)   | 11 (37.9%) | 0.639 |
| Remdesivir                                                     | 19 (42.2%)  | 5 (31.2%)   | 14 (48.3%) | 0.429 |
| Dexamethasone                                                  | 29 (64.4%)  | 10 (62.5%)  | 19 (65.5%) | 1.00  |
| Monoclonal antibody treatment with Sotrovimab                  | 16 (35.6%)  | 1 (6.3%)    | 15 (51.7%) | 0.003 |
| Monoclonal antibody treatment with REGN-COV2                   | 7 (15.6%)   | 2 (12.5%)   | 5 (17.2%)  | 1.00  |
| Convalescent plasma                                            | 2 (4.4%)    | 2 (12.5%)   | 0 (0.0%)   | 0.121 |
| Hospital stay length, median (IQR)                            | 6 (4–12)    | 12 (5–18)   | 4 (3–7)    | 0.058 |
| Admission to ICU, n (%)                                        | 11 (24.4%)  | 6 (37.5%)   | 5 (17.2%)  | 0.161 |
| Death within 30 days of positive SARS-CoV-2 PCR test, n (%)    | 5 (11.1%)   | 3 (18.8%)   | 2 (6.9%)   | 0.330 |

Abbreviations: ICU, intensive care unit; IQR, interquartile range; mTOR, mammalian target of rapamycin; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory coronavirus 2.

*Missing data from 22 infections (8 unvaccinated and 14 vaccinated).
hospital admission in participants who received outpatient monoclonal antibodies. The cumulative incidence of first-positive SARS-CoV-2 PCR test was higher in kidney transplant recipients than in liver transplant recipients, but there were no significant differences in outcome between the groups.

Vaccination against SARS-CoV-2 in Denmark was initiated on December 27, 2020 and SOT recipients were prioritized for early vaccination. We started follow-up on December 27, 2020, and 1 year later, the cumulative incidence of first-time SARS-CoV-2 PCR test was 10%. Importantly, we found that most SOT recipients did not need hospital admission and lower rates of ICU admission and mortality than previously reported. Studies from the pre-vaccination era found hospitalization rates ranging from 31% to 89%, ICU admission ranging from 11% to 33%, and mortality ranging from 5% to 27%. Several factors may contribute to the lower morbidity and mortality observed. First, extensive and easily accessible SARS-CoV-2 PCR testing combined with Danish national registries provides us with excellent opportunities to detect SOT recipients with mild or even asymptomatic infections. In settings without such opportunities, morbidity and mortality might be overestimated. Importantly, we found incidence of hospitalization, ICU admission, and mortality 30 days after first-positive SARS-CoV-2 PCR test to be lower in vaccinated than in unvaccinated SOT recipients. No previous studies have estimated the impact of SARS-CoV-2 vaccination on hospitalization and ICU admissions in SOT recipients, however, it has been shown that vaccination with mRNA vaccines in the general population reduces the risk of hospitalization, disease progression, and death. We found that receiving three vaccine doses decrease the risk of hospital admission by 58%. Although, our study is descriptive, and we cannot conclude on causality or conclude that lower rates of hospitalization or mortality in vaccinated SOT recipients are due to vaccines. In a recent study from England, BNT162b2 vaccination was not found to reduce the risk of death in SOT recipients. Furthermore, treatment and management of SOT recipients with COVID-19 has evolved since the start of the pandemic with implementation of evidence-based treatments such as Dexamethasone, Remdesivir, and monoclonal antibodies that may contribute to lower morbidity and mortality. We showed that participants who received outpatient monoclonal antibodies had a tendency to lower risk of hospital admission. Finally, the virulence of the dominant variant may also affect morbidity and mortality. In Denmark, the alpha variant was first reported in November 2020, and from mid-March until June 2021, it was

### Table 4

| Table 4 Risk factors for hospital admission after infection. Univariable and multivariable Cox regression with monoclonal antibody treatment as a time-updated variable |
|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
|                   |                  | Unadjusted model |                  | Adjusted model*  |
|                   |                  | HR              | 95% CI           | p-value          | HR              | 95% CI           | p-value          |
| Age per 10 years  |                  | 7.50            | 0.82–68.34       | 0.074            | 6.05            | 0.71–51.28       | 0.099            |
| Male sex          |                  | 1.47            | 0.77–2.82        | 0.136            | –               | –               | –               |
| Transplantation type (liver Tx as reference) | 1.85 | 0.87–3.95 | 0.110 | 1.93 | 0.52–0.89 | 0.096 |
| Transplanted within the last year from the start of follow-up or after follow-up | 1.34 | 0.53–3.40 | 0.542 | – | – | – |
| Number of vaccines before the infection (0 and 1 as reference) | 2 | 0.64 | 0.33–1.24 | 0.185 | 0.70 | 0.35–1.38 | 0.299 |
| 3 | 0.312 | 0.15–0.67 | 0.003 | 0.42 | 0.19–0.89 | 0.025 |
| Immunosuppressive treatment | Antimetabolite at time of infection (none as reference) | Mycophenolate | 0.81 | 0.33–1.97 | 0.648 | – | – |
|               | Azathioprine     | 0.59            | 0.11–3.30        | 0.550            | –               | –               | –               |
| Corticosteroids at time of infection | 1.49 | 0.60–3.71 | 0.386 | – | – | – |
| CNI or mTOR at time of infection (CNI as reference) | mTOR | 2.82 | 0.74–10.77 | 0.128 | – | – |
|               | None             | 1.47            | 0.34–6.31        | 0.607            | –               | –               | –               |
| Outpatient monoclonal antibody treatment | 0.11 | 0.01–0.76 | 0.026 | 0.15 | 0.02–1.05 | 0.057 |
| Comorbidities     | Cardiovascular disease | 1.51 | 0.79–2.90 | 0.219 | – | – |
|               | Chronic pulmonary disease | 1.15 | 0.50–2.66 | 0.746 | – | – |
|               | Diabetes mellitus | 1.50 | 0.80–2.84 | 0.209 | – | – |

Abbreviations: CI, confidence interval; CNI, calcineurin inhibitor; HR, hazard ratio; mTOR, mamalian target of rapamycin.

*The adjusted model is adjusted for age, transplantation type, number of vaccination, and outpatient monoclonal antibody treatment.
the dominant variant. The delta variant became the dominant variant from July 2021 until December 2021, and the first cases of omicron were detected in November 2021. The median date of the first-positive SARS-CoV-2 PCR test was February 1, 2021, for unvaccinated and November 24, 2021, for the vaccinated transplant recipients. SARS-CoV-2 variants were only reported for about half of the positive SARS-CoV-2 PCR tests. Still, the wild-type and delta variants were the most prevalent SARS-CoV-2 variants among unvaccinated and vaccinated SOT recipients, respectively, compatible with the dominant variants in February and November in the general population. The severity of COVID-19 and risk of hospitalization, ICU admission, and death are not similar among SARS-CoV-2 variants, with the highest risk of adverse outcomes after infection with the delta variant in the general population. A recent study reported a lower risk of adverse outcomes after infection with the omicron variant compared to the delta variant in the general population, however, it remains unknown if this difference also applies to SOT recipients. The severity of COVID is dependent on multiple factors, among them, omicron replicates less efficiently in the lower respiratory tract which can explain a lower severity of COVID.

The cumulative incidence of first SARS-CoV-2 PCR test in kidney transplant recipients was higher than in liver transplant recipients. In line with our findings, kidney transplant recipients were more likely to have SARS-CoV-2 infection than liver transplant recipients in a cohort of SOT recipients from the United States from the pre-vaccination era. Within the post-vaccination era, a recent study from Spain reported a 2.1 times higher incidence ratio for SARS-CoV-2 infection in kidney transplant recipients than in liver transplant recipients. We observed no significant difference between kidney and liver transplant recipients in cumulative incidence of hospitalization. However, in our cohort only kidney transplant recipients were admitted to ICU or died within 30-days after first-positive SARS-CoV-2 PCR test. This is in line with previous studies reporting that COVID-19 in liver transplant recipients was less severe and had fewer adverse outcomes than in kidney transplant recipients. The kidney transplant recipients in our cohort had a higher burden of comorbidity than liver transplant recipients, including diabetes and cardiovascular diseases which are known risk factors for ICU admission and death. The impact of comorbidities is supported by a study from Sweden, where 30-day all-cause mortality was 17% in liver transplant recipients and 9.3% in kidney transplant recipients, and in this study liver transplant recipients had a higher burden of comorbidities. Finally, we previously found kidney transplant recipients to develop less robust antibody responses to BNT162b2 vaccination than liver transplant recipients. Robust antibody responses have been shown to be of importance in protection against disease progression, inferring that differences in immunological responses between kidney and liver transplant recipients may be of importance.

There was a tendency toward a shorter hospital stay among hospitalized SOT recipients in those who were vaccinated than in those who were unvaccinated at time of first-positive SARS-CoV-2 PCR test. Treatments were the same for vaccinated and unvaccinated, except for outpatient and in-hospital monoclonal antibodies, which more frequently were prescribed to the vaccinated SOT recipients. It has been reported that monoclonal antibodies can prevent disease progression in SOT recipients however, vaccination status and SARS-CoV-2 variant were not reported in that study. The impact of monoclonal antibodies seems to depend on the SARS-CoV-2 variant with novel variants exhibiting antibody evasive properties, and the association between monoclonal antibody treatments and length of hospital stay in SOT recipients needs more investigation.

Our study had some limitations. First, treatments and preventive strategies changed during the study period making it difficult to estimate the impact of each measure. Furthermore, the retrospective nature of the study restricts any attempt to conclude on causality between treatments, preventive strategies, and clinical outcomes. Lastly, the median date of first-positive SARS-CoV-2 PCR test and consequently the SARS-CoV-2 variants for unvaccinated and vaccinated SOT recipients were different, which might affect the results. Our study also had strengths; this is the first large real-life study of morbidity and mortality in SOT recipients who were homogenously vaccinated with mRNA vaccine. Furthermore, we had complete nationwide SARS-CoV-2 PCR test data from MiBa. This combined with extensive and easily accessible testing provides the opportunity to report asymptomatic and mild SARS-CoV-2 infections allowing qualified estimations of hospitalization and mortality rates. Finally, although we did not report the variant in all positive SARS-CoV-2 PCR tests, extensive whole-genome sequencing in Denmark allowed us to report the variant in half of the positive SARS-CoV-2 PCR tests.

In conclusion, SOT recipients remain at high risk of SARS-CoV-2 infections and adverse outcomes after SARS-CoV-2 infections even in the vaccination era. Vaccinated SOT recipients seem to be at lower risk of adverse outcomes than unvaccinated SOT recipients after SARS-CoV-2 infection, however, further studies looking into the effectiveness of preventive measures such as monoclonal antibodies and additional vaccinations are warranted. Finally, investigations of morbidity and mortality associated with emerging SARS-CoV-2 variant infections in SOT recipients are needed, as is continued surveillance of SARS-CoV-2 vaccines’ effectiveness in protecting SOT recipients from SARS-CoV-2 associated morbidity and mortality as new variants emerge.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Sebastian Rask Hamm https://orcid.org/0000-0002-2583-3442
Omid Rezahosseini https://orcid.org/0000-0003-2198-1904
Dina Leth Møller https://orcid.org/0000-0002-3909-0643
Jenny Dahl Knudsen https://orcid.org/0000-0002-8699-9956
reduces hospitalization and death in COVID-19 positive abdominal transplant recipients. *Transplantation*. 2022;106(2):e153-e157. doi:10.1097/TP.0000000000003953

36. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab. *N Engl J Med*. 2021;385(21):1941-1950. doi:10.1056/NEJMOA2107934

37. Lyngse FP, Mølbak K, Skov RL, et al. Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load. *Nat Commun*. 2021;12(1):7251. doi:10.1038/s41467-021-27202-x

38. Lyngse FP, Mølbak K, Denwood M, et al. Effect of Vaccination on Household Transmission of SARS-CoV-2 Delta VOC. *medRxiv*. Published Online January 2022:2022.01.06.22268841. doi:10.1101/2022.01.06.22268841

39. Espenhain L, Funk T, Overvad M, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. *Euro Surveill Bull Eur sur les Mal Transm = Eur Commun Dis Bull*. 2021;26(50). doi:10.2807/1560-7917.ES.2021.26.50.2101146

40. Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. *Lancet Infect Dis*. 2021;21(11):1507-1517. doi:10.1016/S1473-3099(21)00290-5

41. Bager P, Wohlfahrt J, Rasmussen M, Albertsen M, Krause TG. Hospitalisation associated with SARS-CoV-2 delta variant in Denmark. *Lancet Infect Dis*. 2021;21(10):1351. doi:10.1016/S1473-3099(21)00580-6

42. Cevik M, Mishra S. SARS-CoV-2 variants and considerations of inferring causality on disease severity. *Lancet Infect Dis*. 2021;21(11):1472-1474. doi:10.1016/S1473-3099(21)00338-8

43. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *Lancet*. 2022;399:1303-1312. doi:10.1016/S0140-6736(22)00462-7

44. Hui KPY, Ho JCW, Cheung M, et al. SARS-CoV-2 omicron variant replication in human bronchus and lung ex vivo. *Nature*. 2022;603(7902):715-720. doi:10.1038/s41586-022-04479-6

45. Ślusarczyk A, Tracz A, Gronkiewicz M, Jureczko L, Bączkowska T. Outcomes of COVID-19 in hospitalized kidney and liver transplant recipients: a single-center experience. *Polish Arch Intern Med*. 2021;131(11):16070. doi:10.20452/pamw.16070

46. Raja MA, Mendoza MA, Villavicencio A, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. *Transplant Rev (Orlando)*. 2021;35(1):100588. doi:10.1016/j.trre.2020.100588

47. Vinson AJ, Dai R, Agarwal G, et al. Sex and organ-specific risk of major adverse renal or cardiac events in solid organ transplant recipients with COVID-19. *Am J Transplant*. 2021;22:1-15. doi:10.1111/AJT.16865

48. Kim L, Garg S, O’Halloran A, et al. Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-associated hospitalization surveillance network (COVID-NET). *Clin Infect Dis*. 2021;72(9):e206-e214. doi:10.1093/cid/ciaa1012

49. Dispinseri S, Secchi M, Pirillo MF, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. *Nat Commun*. 2021;12(1):1-12. doi:10.1038/s41467-021-22958-8

50. Iketani S, Liu L, Guo Y, et al. Antibody evasion properties of SARS-CoV-2 omicron sublineages. Nat 2022. Published online March 3, 2022:1-1. doi:10.1038/s41586-022-04594-4

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Hamm SR, Rezahosseini O, Møller DL, et al. Incidence and severity of SARS-CoV-2 infections in liver and kidney transplant recipients in the post-vaccination era: Real-life data from Denmark. *Am J Transplant*. 2022;22:2637-2650. doi: 10.1111/ajt.17141